Thursday, December 10, 2009
MicroRNAs in Ovarian Carcinomas
| Medline Abstract
N Dahiya, Lab Cell Molec Biol, NIH, Baltimore, United States.
|  | |||||||||||
| ||||||||||||
| ||||||||||||
| ||||||||||||
| The molecular mechanisms involved in epithelial ovarian cancer initiation and progression are just beginning to be elucidated. In particular, it has become evident that microRNAs (miRNAs), a class of molecules that post-trancriptionally regulates gene expression, play a major role in ovarian tumorigenesis. Several miRNA profiling studies have identified changes in miRNA patterns that take place during ovarian cancer development. While most deregulated miRNAs are down-regulated in cancer, and may therefore act as tumor suppressors, others are elevated and may represent novel oncogenes in this disease. A number of miRNAs identified as aberrantly expressed in ovarian carcinoma have been shown to have important functional roles in cancer development and may therefore represent targets for therapy. In addition, some of the miRNA patterns may have prognostic significance. The identification of functional targets represents a major hurdle in our understanding of miRNA function in ovarian carcinoma, but significant progress is being made. It is hoped that a better understanding of the miRNA expression and roles in ovarian cancer may provide new avenues for the detection, diagnosis, and therapy of this deadly disease. PMID: 19903743 | ||||||||||||
Wednesday, December 09, 2009
Mantra 2009 programme conference outline including abstracts
Cancer Family Study, Australasian Colorectal
Cancer Family Study, Australian Ovarian Cancer
Study, Family Cancer Clinics of Australia and New
Zealand & kConFab
Lynch syndrome: still not a familiar picture.
CASE PRESENTATION: A large Lynch syndrome family with 15 affected family members and involvement in 7 organs is reported. It illustrates a lack of awareness and knowledge about this hereditary tumor syndrome among doctors as well as patients. None of the described family members underwent presymptomatic screening on the basis of the family history.
red flags for familal forms of cancer susceptibility - excerpt
The general clinical features that raise the suspicion of a familial form of cancer susceptibility in a patient diagnosed with any type of malignancy include [1]:
* A cancer that occurs at an unusually young age compared with its usual presentation
* The development of multiple tumors in a single organ, or bilateral development in tumors in paired organs
* The development of more than one primary tumor of any type
* A family history of cancer of the same type or related type in one or more first-degree relatives
* A high rate of cancer occurrence in the family
* Cancer occurring in an individual or within a family with congenital anomalies or birth defects
Expanded Extracolonic Tumor Spectrum in MUTYH-Associated Polyposis
Results
Duodenal polyposis occurred in 17% of cases; the relative risk (SIR) of duodenal cancer was 129 (95% confidence interval [CI]: 16–466), whereas the lifetime risk was 4%. The incidence of extraintestinal malignancies among cases was almost twice that of the general population (SIR: 1.9; 95% CI: 1.4–2.5), with a lifetime risk of 38%. We observed a significant increase in the incidence of ovarian, bladder, and skin cancers (SIR: 5.7, 7.2, and 2.8, respectively) and a trend of increased risk of breast cancer among cases. The median ages of onset of these 4 malignancies ranged from 51 to 61 years. In contrast to familial adenomatous polyposis, no desmoid tumors were observed, but sebaceous gland tumors, characteristic of the Muir-Torre variant of Lynch syndrome, occurred in 5 patients.
Conclusions
The relative risks for several extraintestinal malignancies increased in patients with MAP, but based on the spectrum of cancers (which overlaps with that of Lynch syndrome) and the relatively advanced age at onset, intensive surveillance measures other than frequent endoscopy are unlikely to be helpful to patients with MAP.
Three synchronous primary carcinomas in a patient with HNPCC associated with a novel germline mutation in MLH1: Case report
note fig. 2 and reference to ovarian cancer (?)
Three synchronous primary carcinomas in a patient with HNPCC associated with a novel germline mutation in MLH1: Case report
Three synchronous primary carcinomas in a patient with HNPCC associated with a novel germline mutation in MLH1: Case report
Tuesday, December 08, 2009
gene called MAGP2 -- not previously associated with any type of cancer -- was overexpressed in papillary serous ovarian tumors of patients
A multi-institutional study has identified a potential personalized treatment target for the most common form of ovarian cancer. In the December 8 issue of Cancer Cell, the research team describes finding that a gene called MAGP2 -- not previously associated with any type of cancer -- was overexpressed in papillary serous ovarian tumors of patients who died more quickly. They also found evidence suggesting possible mechanisms by which MAGP2 may promote tumor growth.
VANCOUVER COASTAL HEALTH RESEARCH INSTITUTE | Unique genetic pathology centre set to change the way we treat cancer
"...ovarian cancer is at least five distinct diseases..."
Patient Relations "Road Show" at University Health Network :: Vol. 12 No. 4 2009 :: Healthcare Quarterly :: Longwoods Publishing
Patient Relations "Road Show" at University Health Network :: Vol. 12 No. 4 2009 :: Healthcare Quarterly :: Longwoods Publishing: "Overall, across all sites, the results of our program have generally been positive; 53.9% felt that the in-service met their expectations, and 45.9% felt that their expectations were exceeded."
Subscribe to:
Posts
(
Atom
)
